• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Century Therapeutics Inc (NQ: IPSC )

    2.380 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 2.380
    Bid (Size) 2.220 (3)
    Ask (Size) 2.890 (13)
    Prev. Close 2.380
    Today's Range 2.380 - 2.380
    52wk Range 1.280 - 5.510
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    5 Analysts Assess Century Therapeutics: What You Need To Know
    Via Benzinga
    Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting
    From Century Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -34.62%
    -34.62%
    1 Month
    -7.03%
    -7.03%
    3 Month
    -24.44%
    -24.44%
    6 Month
    -45.03%
    -45.03%
    1 Year
    -21.97%
    -21.97%

    More News

    Read More
    Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    IPSC Stock Earnings: Century Therapeutics Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Century Therapeutics: Q4 Earnings Insights
    Via Benzinga
    Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing
    Via Benzinga
    Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    IPSC Stock Earnings: Century Therapeutics Misses EPS, Misses Revenue for Q4 2023
    Via InvestorPlace
    Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    3 Millionaire-Maker Under-$10 Stocks to Buy in February 2024
    Via InvestorPlace
    Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    IN8bio's Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising Data
    Via Benzinga
    Russell 2000 Rallies To 16-Month Highs: Best Performing Small-Cap Stocks Popping Over 80% In December
    Via Benzinga
    Topics ETFs
    Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential
    Via InvestorPlace
    Harnessing The Power Of Gamma-Delta T Cells In Cancer Therapy: IN8bio's Innovative Approach
    Via Benzinga
    Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
    From Century Therapeutics, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.